CPT 93702Cardiology

Bis xtracell fluid analysis

CPT code 93702 covers bioimpedance spectroscopy (BIS) extracellular fluid analysis, a non-invasive test that measures fluid distribution in the body using electrical signals. This test is commonly used to assess fluid status in patients with heart failure, kidney disease, or lymphedema.

Showing rates for

National Average

Base Medicare rate

$114.83

This calculator gives a typical-case estimate using standard Medicare modifier rules. Actual payment depends on payer policies, documentation, code-specific CMS status indicators, and locality. Verify before billing.

RVU breakdown

Work RVU

PE RVU (NF)

3.53

MP RVU

0.02

Total RVU

3.55

Conversion factor: 32.3465 · Source: CMS MPFS RVU25A · Confidence: High

NCCI bundling edits

Loading bundling edits…

Billing tips

Document specific clinical indication (CHF exacerbation, dialysis adequacy, lymphedema progression) as 93702 faces frequent medical necessity denials without clear justification
Impact: Reduces denial rate by 40-60%; ensures full $114.83 payment versus $0 for denied claims
Verify LCD coverage policies as many Medicare MACs limit frequency to once per 30 days or require prior authorization for chronic monitoring
Impact: Prevents systematic denials; some MACs deny 100% of claims exceeding frequency limits without prior authorization
Link to appropriate ICD-10 codes such as I50.x (heart failure), N18.6 (ESRD), or I89.0 (lymphedema) rather than generic signs/symptoms codes
Impact: Increases first-pass payment rate by 35-50%; symptom-only coding triggers automatic medical necessity reviews
Bill on the same day as E/M service only when test results directly impact treatment decisions documented in the visit note
Impact: Prevents bundling issues; maintains separate $114.83 payment rather than inclusion in E/M reimbursement
Ensure device used meets FDA clearance for extracellular fluid measurement and document device name/model in medical record
Impact: Addresses potential post-payment audits; lack of FDA-cleared device documentation can trigger full recoupment of payments
Avoid billing 93702 more frequently than clinically justified as utilization outliers face 100% medical record audits by Medicare contractors
Impact: Providers billing >4 times per patient annually face audit rates 300% higher than peers

Live Field Datano reports yet

Real billers contribute denial patterns and appeal strategies for this code. Once 5+ reports come in, you’ll see live aggregated data here — the only place this exists, free.

Working with CPT 93702?

Get the free Revenue Protection Toolkit — the denial triggers, modifier pitfalls, and bundling conflicts that quietly cost you reimbursement. Instant download.

Help build the field knowledge

MedPayIQ gets smarter as billers contribute. If you've had this code denied, share what happened so others learn from it. Anonymous, no patient info.

Related actions

Frequently asked questions

What is the Medicare reimbursement rate for CPT 93702 in 2025?

The 2025 Medicare national average reimbursement for CPT 93702 is $114.83 for both facility and non-facility settings. This rate is based on 3.55 total RVUs multiplied by the 2025 conversion factor of 32.3465. Actual payment may vary based on geographic location and payer-specific fee schedules.

How often can CPT 93702 be billed for the same patient?

Medicare and most commercial payers limit 93702 to once per 30 days for routine monitoring, though more frequent testing may be covered with documentation of acute clinical changes. Providers should verify specific LCD policies in their jurisdiction, as some Medicare Administrative Contractors require prior authorization for repeat testing beyond quarterly intervals.

What diagnosis codes support medical necessity for CPT 93702?

Primary diagnosis codes supporting 93702 include I50.x (heart failure variants), N18.6 (end-stage renal disease), I89.0 (lymphedema), E87.70 (fluid overload), and R60.x (edema). Payers typically deny claims with symptom-only codes unless linked to a documented underlying fluid management disorder requiring objective monitoring.

Can CPT 93702 be billed with an E/M service on the same day?

Yes, 93702 can be billed separately with an E/M service when the bioimpedance testing is medically necessary and results directly influence treatment decisions during that visit. Documentation must clearly show the test was not a routine screening but rather prompted by specific clinical findings requiring immediate fluid status assessment.

What is the difference between CPT 93702 and 93701?

CPT 93702 specifically describes bioimpedance spectroscopy for extracellular fluid analysis, while 93701 covers bioimpedance cardiovascular analysis (also called impedance cardiography). These are distinct tests: 93701 measures cardiac output and hemodynamics, whereas 93702 measures fluid compartments and volume status. They address different clinical questions and should not be confused in billing.

Do I need special equipment certification to bill CPT 93702?

While CPT coding does not require specific certification, the device used must be FDA-cleared for bioimpedance spectroscopy and extracellular fluid measurement. Some payers require documentation of device validation and calibration. Staff performing the test should have manufacturer training, and the interpreting physician must document qualification to interpret bioimpedance results.

Why do some insurers deny CPT 93702 as experimental?

Some payers have not updated coverage policies to recognize bioimpedance spectroscopy as standard of care, particularly for indications beyond lymphedema and dialysis monitoring. Appeals should include FDA clearance documentation, published clinical guidelines from cardiology/nephrology societies, and peer-reviewed evidence demonstrating clinical utility for the specific indication billed.